River Road Asset Management LLC Buys 45,762 Shares of Enovis Co. (NYSE:ENOV)

River Road Asset Management LLC increased its stake in Enovis Co. (NYSE:ENOV) by 3.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,238,357 shares of the company’s stock after purchasing an additional 45,762 shares during the period. River Road Asset Management LLC owned 2.18% of Enovis worth $54,339,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the stock. Amalgamated Bank raised its position in shares of Enovis by 1.0% during the 4th quarter. Amalgamated Bank now owns 25,887 shares of the company’s stock valued at $1,136,000 after acquiring an additional 264 shares during the last quarter. Pinnacle Bancorp Inc. raised its position in shares of Enovis by 54.5% during the 4th quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company’s stock valued at $37,000 after acquiring an additional 300 shares during the last quarter. Arizona State Retirement System raised its position in shares of Enovis by 2.6% during the 4th quarter. Arizona State Retirement System now owns 16,208 shares of the company’s stock valued at $711,000 after acquiring an additional 414 shares during the last quarter. Aigen Investment Management LP raised its position in shares of Enovis by 5.1% during the 3rd quarter. Aigen Investment Management LP now owns 8,859 shares of the company’s stock valued at $381,000 after acquiring an additional 430 shares during the last quarter. Finally, UMB Bank n.a. raised its position in shares of Enovis by 128.2% during the 4th quarter. UMB Bank n.a. now owns 778 shares of the company’s stock valued at $34,000 after acquiring an additional 437 shares during the last quarter. Institutional investors own 98.45% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Needham & Company LLC dropped their target price on shares of Enovis from $65.00 to $64.00 and set a “buy” rating for the company in a research report on Thursday, February 27th.

Enovis Price Performance

Shares of ENOV stock opened at $35.55 on Tuesday. Enovis Co. has a 12-month low of $35.14 and a 12-month high of $62.79. The firm has a market capitalization of $2.02 billion, a price-to-earnings ratio of -16.23 and a beta of 2.05. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40. The firm has a fifty day moving average of $43.90 and a 200-day moving average of $43.98.

Enovis (NYSE:ENOV) last announced its quarterly earnings results on Wednesday, February 26th. The company reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.92 by $0.06. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The company had revenue of $560.98 million during the quarter, compared to analyst estimates of $555.14 million. On average, equities research analysts forecast that Enovis Co. will post 2.79 earnings per share for the current year.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.